The Bielefeld-based Dr Wolff Group increased its turnover by more than six per cent to 384 million euros last year, primarily through product innovations and growing international sales. Whilst the German market, at around €227 million, still accounts for just under 60 per cent of total turnover, international turnover – particularly in Poland, Hungary and Spain, as well as North America and China – grew by almost 13 per cent to €157 million. Further momentum came from new formulations for Alpecin and Plantur, as well as dental care products developed in-house, the company announced. The global roll-out of further Plantur innovations and new Alpecin products is planned for this year. Especially in highly dynamic and competitive markets, differentiation through efficacy achieved by research is crucial, said Eduard R. Dörrenberg, CEO of the Dr. Wolff Group. Further information …